Genprex shares surge 20.70% premarket after securing Japanese and EU patents for Reqorsa gene therapy in cancer treatment combinations.

Genprex Inc. surged 20.70% in premarket trading following announcements that the Japanese Patent Office and European Patent Office granted patents for its REQORSA gene therapy in combination with PD-1/PD-L1 antibodies to treat cancer. These approvals expand intellectual property protection in key markets, reinforcing Genprex’s portfolio for its Acclaim-3 clinical trial targeting small cell lung cancer. The patents align with ongoing Phase 2 expansion of Acclaim-3, which is supported by FDA Fast Track and Orphan Drug designations, and underscore the company’s strategic advancements in oncology. Multiple news outlets, including Investing.com, directly linked the stock’s sharp rise to the patent decisions, which reduce competitive risks and enhance long-term commercial potential for REQORSA-based therapies.